Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer

Jin Hur, Hye Jeong Lee, Ji E. Nam, Young J. Kim, Yoo J. Hong, Hee Y. Kim, Se K. Kim, Joon Chang, Joo Hang Kim, Kyung Y. Chung, Hye S. Lee, Byoung W. Choi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue, therefore many biomarker candidates will be present in high concentrations. The aim of this study was to prospectively assess and validate the tumor markers CYFRA 21-1, CEA, and SCC in cytological fluid obtained from NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer (NSCLC).Methods: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21-1, CEA, and SCC were measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21-1, 5 ng/mL and 0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC.Results: Of 194 patients, 139 patients (71.6%) had NSCLC and 55 (28.4%) had benign lesions. Sensitivity increased significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21-1: 95% versus 83.5%, p < 0.001, CEA: 92.1% versus 83.5%, p = 0.002, SCC: 91.4% versus 83.5%, p = 0.003). Accuracy improved significantly for NAB combined with cytological CYFRA 21-1 compared with NAB alone (95.9% versus 88.1%, p < 0.001). The area under curve (AUC) of NAB with cytological CYFRA 21-1 was significantly larger than for NAB alone (0.966 versus 0.917, p = 0.009).Conclusion: Of the tested tumor markers, cytological fluid measurements of CYFRA 21-1 improved the diagnostic performance of NAB for NSCLC.

Original languageEnglish
Article number392
JournalBMC cancer
Volume12
DOIs
Publication statusPublished - 2012 Sep 7

Fingerprint

Needle Biopsy
Tumor Biomarkers
Non-Small Cell Lung Carcinoma

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Hur, Jin ; Lee, Hye Jeong ; Nam, Ji E. ; Kim, Young J. ; Hong, Yoo J. ; Kim, Hee Y. ; Kim, Se K. ; Chang, Joon ; Kim, Joo Hang ; Chung, Kyung Y. ; Lee, Hye S. ; Choi, Byoung W. / Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. In: BMC cancer. 2012 ; Vol. 12.
@article{83885ecb80254eba81ccc3ebb70e9720,
title = "Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer",
abstract = "Background: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue, therefore many biomarker candidates will be present in high concentrations. The aim of this study was to prospectively assess and validate the tumor markers CYFRA 21-1, CEA, and SCC in cytological fluid obtained from NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer (NSCLC).Methods: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21-1, CEA, and SCC were measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21-1, 5 ng/mL and 0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC.Results: Of 194 patients, 139 patients (71.6{\%}) had NSCLC and 55 (28.4{\%}) had benign lesions. Sensitivity increased significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21-1: 95{\%} versus 83.5{\%}, p < 0.001, CEA: 92.1{\%} versus 83.5{\%}, p = 0.002, SCC: 91.4{\%} versus 83.5{\%}, p = 0.003). Accuracy improved significantly for NAB combined with cytological CYFRA 21-1 compared with NAB alone (95.9{\%} versus 88.1{\%}, p < 0.001). The area under curve (AUC) of NAB with cytological CYFRA 21-1 was significantly larger than for NAB alone (0.966 versus 0.917, p = 0.009).Conclusion: Of the tested tumor markers, cytological fluid measurements of CYFRA 21-1 improved the diagnostic performance of NAB for NSCLC.",
author = "Jin Hur and Lee, {Hye Jeong} and Nam, {Ji E.} and Kim, {Young J.} and Hong, {Yoo J.} and Kim, {Hee Y.} and Kim, {Se K.} and Joon Chang and Kim, {Joo Hang} and Chung, {Kyung Y.} and Lee, {Hye S.} and Choi, {Byoung W.}",
year = "2012",
month = "9",
day = "7",
doi = "10.1186/1471-2407-12-392",
language = "English",
volume = "12",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

Hur, J, Lee, HJ, Nam, JE, Kim, YJ, Hong, YJ, Kim, HY, Kim, SK, Chang, J, Kim, JH, Chung, KY, Lee, HS & Choi, BW 2012, 'Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer', BMC cancer, vol. 12, 392. https://doi.org/10.1186/1471-2407-12-392

Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. / Hur, Jin; Lee, Hye Jeong; Nam, Ji E.; Kim, Young J.; Hong, Yoo J.; Kim, Hee Y.; Kim, Se K.; Chang, Joon; Kim, Joo Hang; Chung, Kyung Y.; Lee, Hye S.; Choi, Byoung W.

In: BMC cancer, Vol. 12, 392, 07.09.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer

AU - Hur, Jin

AU - Lee, Hye Jeong

AU - Nam, Ji E.

AU - Kim, Young J.

AU - Hong, Yoo J.

AU - Kim, Hee Y.

AU - Kim, Se K.

AU - Chang, Joon

AU - Kim, Joo Hang

AU - Chung, Kyung Y.

AU - Lee, Hye S.

AU - Choi, Byoung W.

PY - 2012/9/7

Y1 - 2012/9/7

N2 - Background: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue, therefore many biomarker candidates will be present in high concentrations. The aim of this study was to prospectively assess and validate the tumor markers CYFRA 21-1, CEA, and SCC in cytological fluid obtained from NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer (NSCLC).Methods: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21-1, CEA, and SCC were measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21-1, 5 ng/mL and 0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC.Results: Of 194 patients, 139 patients (71.6%) had NSCLC and 55 (28.4%) had benign lesions. Sensitivity increased significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21-1: 95% versus 83.5%, p < 0.001, CEA: 92.1% versus 83.5%, p = 0.002, SCC: 91.4% versus 83.5%, p = 0.003). Accuracy improved significantly for NAB combined with cytological CYFRA 21-1 compared with NAB alone (95.9% versus 88.1%, p < 0.001). The area under curve (AUC) of NAB with cytological CYFRA 21-1 was significantly larger than for NAB alone (0.966 versus 0.917, p = 0.009).Conclusion: Of the tested tumor markers, cytological fluid measurements of CYFRA 21-1 improved the diagnostic performance of NAB for NSCLC.

AB - Background: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue, therefore many biomarker candidates will be present in high concentrations. The aim of this study was to prospectively assess and validate the tumor markers CYFRA 21-1, CEA, and SCC in cytological fluid obtained from NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer (NSCLC).Methods: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21-1, CEA, and SCC were measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21-1, 5 ng/mL and 0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC.Results: Of 194 patients, 139 patients (71.6%) had NSCLC and 55 (28.4%) had benign lesions. Sensitivity increased significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21-1: 95% versus 83.5%, p < 0.001, CEA: 92.1% versus 83.5%, p = 0.002, SCC: 91.4% versus 83.5%, p = 0.003). Accuracy improved significantly for NAB combined with cytological CYFRA 21-1 compared with NAB alone (95.9% versus 88.1%, p < 0.001). The area under curve (AUC) of NAB with cytological CYFRA 21-1 was significantly larger than for NAB alone (0.966 versus 0.917, p = 0.009).Conclusion: Of the tested tumor markers, cytological fluid measurements of CYFRA 21-1 improved the diagnostic performance of NAB for NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84865824406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865824406&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-12-392

DO - 10.1186/1471-2407-12-392

M3 - Article

C2 - 22954172

AN - SCOPUS:84865824406

VL - 12

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 392

ER -